Neuroscience and Behavioral Physiology

, Volume 46, Issue 4, pp 390–393 | Cite as

An Open Clinical Trial of Cortexin in Cerebral Ischemia

  • V. V. Mashin
  • L. A. Belova
  • O. I. Chaplanova
  • A. F. Khusnullina
  • A. M. Manasyan

Objective. To investigate the efficacy of Cortexin in the treatment of cognitive and affective disorders in cerebral ischemia (AI) developing on the background of arterial hypertension or atherosclerosis. Materials and methods. We present an analysis of the all-Russian screening program for the efficacy of Cortexin, “Cognitive and Affective Disorders in the Treatment of Cerebral Ischemia with Cortexin” (KarKaDÉ), in 50,000 patients with AI developing on the background of arterial hypertension and/or atherosclerosis in 2013 in 70 Russian cities. Results. All patients received Cortexin at a dose of 10 mg/day for 10 days and were investigated before treatment and on days 11 and 30 after the first dose. More extensive analysis was applied to results from the treatment of 500 patients with stage II AI, mean age 63.7 ± 10.23 years. Treatment efficacy was evaluated using a five-point rating scale for subjective and objective neurological symptoms, the five-word memory test, the Schulte test, the MMSE, the Hamilton scales for evaluation of anxiety, and the short form of the Geriatric Depression Scale. Conclusions. Treatment decreased or completely eliminated focal neurological symptomatology and produced positive changes in measures of cognitive impairments, these changes being accompanied by normalization of patients’ emotional status and decreases in the level of depression.


Cortexin chronic cerebrovascular pathology cerebral ischemia neurological deficit cognitive and affective disorders 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    L. A. Belova, V. V. Mashin, Yu. M. Nikitin, and V. G. Belov, Hypertensive Encephalopathy: Clinical-Pathogenetic Subtypes, Classification, and Diagnosis: Monograph, Ulyanovsk State Univ., Ulyanovsk (2010).Google Scholar
  2. 2.
    L. A. Belova, O. V. Gavrilyuk, N. V. Belova, et al., “Effects of antihypertensive treatment on the clinical-psychological characteristics of patients with hypertensive encephalopathy,” Saratov. Med. Zh., 7, No. 4, 866–870 (2011).Google Scholar
  3. 3.
    O. S. Levin and L. V. Golubeva, “Heterogeneity of moderate cognitive disorder: diagnostic and therapeutic aspects,” Consilium Medicum, 12, 106–110 (2006).Google Scholar
  4. 4.
    Z. A. Suslina, M. A. Piradov, Yu. Ya. Varakin, et al., Stroke: Diagnosis, Treatment, Prophylaxis, MEDpress-Inform, Moscow (2009).Google Scholar
  5. 5.
    Z. A. Suslina, A. V. Fonyakin (eds.), L. A. Geraskina, et al., Practical Cardioneurology, IMA-PRESS, Moscow (2010).Google Scholar
  6. 6.
    V. V. Mashin and A. S. Kadykov, Hypertensive Encephalopathy. Clinical Pathogenesis: Monograph, Nauchnoe Izdanie, Ulyanovsk (2002).Google Scholar
  7. 7.
    L. Belova, V. Mashin, and N. Belova, “Hypertensive encephalopathy: the role of arteriovenous interrelations in the formation of its clinical-pathogenetic subtypes,” Exp. Clin. Cardiol., 20, No. 7, 892–898 (2014).Google Scholar
  8. 8.
    R. Baroa, S. Martinez-Espinosa, E. Rodriguez-Garcia, et al., “Poststroke dementia. clinical features and risk factors,” Stroke, 31, 1494–1501 (2000).CrossRefGoogle Scholar
  9. 9.
    O. V. Gavrilyuk, L. A. Belova, N. V. Belova, and V. V. Mashin, “Dyna mics of quality of life and compliance with antihypertensive treatment in patients with hypertensive encephalopathy,” Palliativ. Med. Reabil., No. 1, 28–30 (2011).Google Scholar
  10. 10.
    V. V. Mashin, E. A. Pinkova, L. N. Vinokurov, et al., “Risk factors for hypertensive encephalopathy and potential pathways to their pharmacological correction,” Med. Alman., 14, No. 1, 88–90 (2011).Google Scholar
  11. 11.
    V. V. Mashin, L. A. Belova, O. V. Gavrilyuk, and N. V. Belova, “Effects of antihypertensive treatment on the clinical-psychological characteristics of patients with hypertensive encephalopathy,” Saratov Nauchn. Zh., 7, No. 4, 866–870 (2011).Google Scholar
  12. 12.
    M. M. D’yakonov and P. D. Shabanov, “The question of the neuroprotective action of peptide properties,” Vestn. Voen.-Med. Akad., 33, No. 1, 255–258 (2011).Google Scholar
  13. 13.
    A. A. Skoromets and M. M. D’yakonov (eds.), Neuroprotection in Acute and Chronic Cerebral Circulatory Failure, Nauka, St. Petersburg (2007).Google Scholar
  14. 14.
    A. A. Skoromets and M. M. D’yakonov, Cortexin. Five Years of Experience in Russian Neurology, Nauka, St. Petersburg (2005).Google Scholar
  15. 15.
    P. D. Shabanov, A. A. Lebedev, and A. V. Droblenkov, Behavioral Effects of the Peptide Preparations Cortexin and Noopept in Modulation of the Stress-Antistress Systems in Early Ontogeny, Nauka, St. Petersburg (2009).Google Scholar
  16. 16.
    G. G. Neznamov and E. S. Teleshova, “Results of a comparative study of Noopept and piracetam in the treatment of patients with mild cognitive impairments in organic brain diseases of vascular and traumatic origin,” Zh. Nevrol. Psikhiat., 108, No. 3, 33–42 (2008).Google Scholar
  17. 17.
    R. Hebert, J. Lindsay, and R. Verrault, “Vascular Dementia. Incidence and risk factors in the Canadian Study of Health and Aging,” Stroke, No. 5, 1487–1493 (2000).Google Scholar
  18. 18.
    D. Neary, “Classification of the dementias,” Zh. Nevrol. Psikhiat., No. 1, 61–67 (2000).Google Scholar
  19. 19.
    N. N. Yakhno, “Cognitive disorders in neurological clinical practice,” Nevrol. Zh., 11, No. 1, 4–12 (2006).Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • V. V. Mashin
    • 1
  • L. A. Belova
    • 1
  • O. I. Chaplanova
    • 1
  • A. F. Khusnullina
    • 1
  • A. M. Manasyan
    • 1
  1. 1.Ulyanovsk State UniversityUlyanovskRussia

Personalised recommendations